Viatris (Nasdaq: VTRS), a global healthcare company, today announced that five abstracts from its Phase 3 program evaluating novel fast-acting formulation of meloxicam (MR-107A-02) in ...

Viatris in Egypt, a part of global healthcare company Viatris, announced the launch of Norvasc Val, a combination therapy for ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Erectile dysfunction (ED), a condition often overlooked and stigmatized in Africa due to widespread misinformation, affects ...

Swiss pharma company Idorsia today released encouraging first half 2025 financial results, sending its shares up 8.5% to 2.94 ...

Indiana Attorney General Todd Rokita has secured $720 million in settlements with eight drug makers that manufacture opioid ...

For reference, Seeking Alpha's Quant system is driven by powerful computer processing and SA's special 'Quantamental' ...

A total of 5 analyst ratings have been received for Teva Pharmaceutical Indus, with the consensus rating being Buy. The ...

CEO-to-be Maziar Mike Doustdar will need to stem the company’s tumbling share price as market pressures intensify.

Teva's transformation boosts profit growth and specialty drugs, offering an undervalued opportunity. Click here to read my ...

A Sydney-based pharmaceutical company has collapsed owing creditors over $13m as administrators scramble to find a rescue ...

LENZ Therapeutics' VIZZ earns FDA approval as the first aceclidine-based eye drop to treat presbyopia, with U.S. launch expected in Q4 2025.